Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isotonic fluid, in the context of the Renal Anhydramnios Fetal Therapy (RAFT) trial, refers to a warmed sterile solution (such as Ringer's Lactate or normal saline) supplemented with balanced electrolytes and antibiotics. Developed by Johns Hopkins University in collaboration with the North American Fetal Therapy Network (NAFTNet), this therapeutic intervention is administered via serial percutaneous amnioinfusions to pregnant women whose fetuses suffer from early pregnancy renal anhydramnios (EPRA). The primary mechanism is the physical restoration of amniotic fluid volume, which is essential for fetal lung expansion and development, thereby aiming to prevent lethal pulmonary hypoplasia. The RAFT trial is a multicenter Phase 1 study evaluating the safety and efficacy of this procedure, with a primary endpoint of neonatal survival to successful dialysis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isotonic fluid.